Roy S. Herbst, MD, PhD of Yale Cancer Center talks about EGFR inhibitor resistant patients and how EGFR antibodies may play a role. With over 20 years of experience in treating patients, Roy has seen that patients progressed in some way on these drugs. The data they have for the EGFR antibodies with chemotherapy may give them a hint on the role of these drugs to patients in the future, who might be resistant to EGFR inhibitors. This is, not only for wild-type patients, but also for mutant patients. Furthermore, he also emphasizes their theory can also be used for lung cancer.